Project Grant K01HL171464
Award Date
9/1/24
Completion Date
8/31/25
Dollars Obligated
$261K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Madison, WI 53715, USA
Similar Awards
This Project Grant award of $604,115 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will support an observational study to evaluate the use of advanced imaging technologies, including PET and dynamic contrast-enhanced MRI, to predict the development of progressive pulmonary fibrosis in individuals with non-idiopathic pulmonary fibrosis interstitial lung disease. The study aims to determine if these innovative imaging...
This $5,715,866 federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) aims to fundamentally reshape the understanding of pulmonary fibrosis (PF) by investigating the early disease mechanisms and drivers of pre-clinical progression. The funding will support four integrated research projects and three core functions at the University of Michigan, Vanderbilt University Medical Center, and Translational Genomics Research...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a Project Grant totaling $299,295 to Fibrobiologics LLC to support the preclinical development of a novel therapeutic agent for the treatment of idiopathic pulmonary fibrosis (IPF). The funding, provided through the Cardiovascular Diseases Research program (CFDA 93.837), will enable Fibrobiologics to determine the antifibrotic activity of the peptide M10 in primary lung fibroblasts from IPF patients and evaluate its efficacy in two...
This $595,286 Project Grant award from the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to define the mechanisms governing intracellular collagen sensing and clearance pathways. The award aims to address a key knowledge gap in understanding how collagen is degraded and turned over in the context of idiopathic pulmonary fibrosis (IPF), a fatal lung disease characterized by the accumulation of fibrotic...
This $145,642 Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports the engineering of 3D pulmonary microtissue models to study the role of fibroblast senescence in idiopathic pulmonary fibrosis (IPF). The objective is to develop an in vitro system to evaluate age-associated pathways driving extracellular matrix remodeling by senescent fibroblasts in IPF. Key expected outcomes include: 1) an in vitro microtissue model to...
This $542,402 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) aims to identify small molecule drugs that can reverse the gene expression profile associated with idiopathic pulmonary fibrosis (IPF). The research project, led by a collaborative partnership between Henry Ford Health and Michigan State University Health Sciences, will utilize single-cell RNA sequencing to profile lung tissue and then...
This federal Project Grant award, with a total funding amount of $2,323,927.00 over the period of July 15, 2024 to June 30, 2028, was granted by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The grant supports research to understand the mechanisms underlying the emergence and functional role of inflammatory fibroblasts in the development of pulmonary fibrosis. The project aims to utilize single-cell RNA sequencing, lineage...
This $805,845 four-year federal Project Grant award (R01HL175948) from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports the development and testing of a novel Lung Precision Drug Delivery System (LPDDS). The goal is to create a targeted therapeutic approach that can actively transport anti-fibrotic agents directly into lung tissue to comprehensively block the activation and differentiation of myofibroblasts, a key...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $306,748 to Mechanobiologix LLC to develop a stiffness-based drug discovery platform for Idiopathic Pulmonary Fibrosis (IPF). The project aims to integrate micro- and macro-scale stiffness measurements of human precision-cut lung slices (HPCLS) with traditional IPF endpoints to evaluate the therapeutic and preventive...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $122,788 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to establish a pharmacokinetic model for absolute quantification of pulmonary perfusion and microvascular parameters, and validate this model in large animal models of idiopathic pulmonary fibrosis (IPF). The goal is to use dynamic...